Agoracom Blog Home

Archive for the ‘Medical Marijuana Stocks’ Category

Namaste $N.ca Announces Product Acquisition Agreement With Aphria Inc. $APH.ca

Posted by AGORACOM-JC at 9:49 AM on Wednesday, September 20th, 2017

Nlogo

  • Signed a Product Acquisition Agreement with Aphria Inc. (TSX:APH) (OTCQB:APHQF), to supply medical cannabis through Namaste’s Cannmart facility in Ontario, Canada
  • Agreement represents further progress for Namaste in securing supply agreements with high quality producers of medical cannabis

VANCOUVER, British Columbia, Sept. 20, 2017 — Namaste Technologies Inc. (“Namaste” or the “Company”) (CSE:N) (FRANKFURT:M5BQ) (OTCMKTS:NXTTF) is pleased to announce that it has signed a Product Acquisition Agreement (the “Agreement”) with Aphria Inc. (“Aphria”) (TSX:APH) (OTCQB:APHQF), to supply medical cannabis through Namaste’s Cannmart facility in Ontario, Canada.

The Agreement represents further progress for Namaste in securing supply agreements with high quality producers of medical cannabis. Namaste intends to build on its current product offerings through its distribution license, by creating an online marketplace that is inclusive of medical cannabis for our Canadian customers. Namaste is pleased to have brought on Aphria, one of Canada’s leading licensed producers focused on production of pharmaceutical grade medical cannabis products.

About Aphria Inc.

Aphria Inc., one of Canada’s lowest cost producers, produces, supplies and sells medical cannabis. Located in Leamington, Ontario, the greenhouse capital of Canada, Aphria is truly powered by sunlight, allowing for the most natural growing conditions available. It is committed to providing pharma-grade medical cannabis, superior patient care while balancing patient economics and returns to shareholders. It is the first public licensed producer to report positive cash flow from operations and the first to report positive earnings in consecutive quarters.

Management Commentary

Sean Dollinger, President and CEO of Namaste comments: “We are very pleased to be working with Aphria, who we believe to be one of the top Canadian producers of the highest quality medical cannabis products. Our goal is to create an online marketplace for our patients that will offer a variety of products sourced from various producers in Canada and overseas. We plan to leverage our existing database of Canadian consumers along with our expertise in e-commerce to provide a unique platform for medical patients to access. We are excited to offer Aphria product to our Cannmart patients shipped from our facility in Toronto, Ontario.”

About Namaste Technologies Inc.

Namaste Technologies Inc. is an emerging leader in vaporizer and accessories space. Namaste has 26 ecommerce retail stores in 20 countries, offers the largest range of brand name vaporizers products on the market and is actively manufacturing and launching multiple unique proprietary products for retail and wholesale distribution. The Company is currently focused on expanding its product offering, acquisitions and strategic partnerships, and entering new markets globally.

On behalf of the Board of Directors

“Sean Dollinger”
Chief Executive Officer
Direct: +1 (786) 389 9771
Email: info@namastevapes.com

Further information on the Company and its products can be accessed through the links below:

www.namastetechnologies.com

www.namastevaporizers.com

www.namastevaporizers.co.uk

www.everyonedoesit.com

www.everyonedoesit.co.uk

FORWARD LOOKING INFORMATION This press release contains forward-looking information based on current expectations. These statements should not be read as guarantees of future performance or results. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements. Although such statements are based on management’s reasonable assumptions, Namaste assumes no responsibility to update or revise forward looking information to reflect new events or circumstances unless required by law. Although the Company believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because the Company can give no assurance that they will prove to be correct. Since forward looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. These statements speak only as of the date of this press release. Actual results could differ materially from those currently anticipated due to a number of factors and risks including various risk factors discussed in the Company’s disclosure documents which can be found under the Company’s profile on www.sedar.com. This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The CSE has neither reviewed nor approved the contents of this press release.

Tetra Bio-Pharma $TBP.ca to engage in co-development and distribution partnership with major healthcare specialty distributor

Posted by AGORACOM-JC at 8:19 AM on Wednesday, September 20th, 2017

Tbp large new

  • Announced that it has signed a letter of intent (LOI) with a major player of the healthcare specialty industry
  • Privately-owned partner has a pan-Canadian distribution network that reaches up to 7000 specialized healthcare professionals
  • First product will be launched in Q1 2018 with subsequent products already in development for the remainder of 2018
  • Tetra and its partner will be tapping into the overall Over-The-Counter topical analgesics market of more than $300 million in sales in Canada, with the US market reaching over $2.9 billion, according to an IMS analysis

OTTAWA, ONTARIO–(Sept. 20, 2017) – Tetra Bio-Pharma Inc. (“Tetra” or the “Company“) (TSX VENTURE:TBP)(OTCQB:TBPMF), today announced that it has signed a letter of intent (LOI) with a major player of the healthcare specialty industry.

This privately-owned partner, which asked to remain unnamed for the time being, has a pan-Canadian distribution network that reaches up to 7000 specialized healthcare professionals. Through their distribution channel, they have access to over 3000 specialized healthcare businesses in Canada and already work with a worldwide network of partners, including the USA.

Tetra and its partner are working together to develop a new line of products, leveraging Tetra’s clinical and product development expertise. The first product will be launched in Q1 2018 with subsequent products already in development for the remainder of 2018. Tetra and its partner will be tapping into the overall Over-The-Counter (OTC) topical analgesics market of more than $300 million in sales in Canada, with the US market reaching over $2.9 billion, according to an IMS analysis. Both companies are expecting to grab a share if the specialized OTC topical analgesics market in a short period of time and could see sales generated from this distribution channel reaching $3 million for Canada in the 1st year. Since the initial launch phase will be focused on the Canadian market, further guidance will be provided as Tetra’s partner gets ready to launch in the US.

« We’re excited to enter this specialized market as there is a significant need for our clinical expertise in product development. This partnership opens a new distribution channel for our pharmaceutical retail division not only in Canada, but also worldwide through their active partners in the US and Europe. Tetra remains committed and is actively developing partnerships to generate a significant revenue stream. This partnership demonstrates our team’s focus and dedication in accelerating our commercialization strategy towards selling a specialized line of products in our pharmaceutical retail business, » comments Bernard Fortier, CEO of Tetra Bio-Pharma.

About Tetra Bio-Pharma:

Tetra Bio-Pharma (TSX VENTURE:TBP)(OTCQB:TBPMF) is a biopharmaceutical leader in cannabinoid-based drug discovery and clinical development. Tetra has three core expertise: clinical research, pharmaceutical promotion and retail commercialization of cannabinoid-based drugs.

More information at: www.tetrabiopharma.com.

Source: Tetra Bio-Pharma

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Forward-looking statements

Some statements in this release may contain forward-looking information. All statements, other than of historical fact, that address activities, events or developments that the Company believes, expects or anticipates will or may occur in the future (including, without limitation, statements regarding potential acquisitions and financings) are forward-looking statements. Forward-looking statements are generally identifiable by use of the words “may”, “will”, “should”, “continue”, “expect”, “anticipate”, “estimate”, “believe”, “intend”, “plan” or “project” or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements are subject to a number of risks and uncertainties, many of which are beyond the Company’s ability to control or predict, that may cause the actual results of the Company to differ materially from those discussed in the forward-looking statements. Factors that could cause actual results or events to differ materially from current expectations include, among other things, without limitation, the inability of the Company, through its wholly-owned subsidiary, GrowPros MMP Inc., to obtain a licence for the production of medical marijuana; failure to obtain sufficient financing to execute the Company’s business plan; competition; regulation and anticipated and unanticipated costs and delays, and other risks disclosed in the Company’s public disclosure record on file with the relevant securities regulatory authorities. Although the Company has attempted to identify important factors that could cause actual results or events to differ materially from those described in forward-looking statements, there may be other factors that cause results or events not to be as anticipated, estimated or intended. Readers should not place undue reliance on forward-looking statements. The forward-looking statements included in this news release are made as of the date of this news release and the Company does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.

Tetra Bio-Pharma Inc.
Anne-Sophie Courtois
Vice-President Marketing & Communication
1 (514) 360-8040 Ext. 210
Anne-sophie.courtois@tetrabiopharma.com
www.tetrabiopharma.com

Namaste $N.ca Announces Supply Agreement With Israel-Based #Cannabis Producer Cannbit Ltd. #MMJ #Vapes

Posted by AGORACOM-JC at 8:32 AM on Friday, September 15th, 2017

Nlogo

  • Wholly owned subsidiary, Cannmart Inc, has signed a supply agreement with Israeli-based producer Cannbit
  • Will supply medical cannabis products sourced from Cannbit in Israel,
  • To be sold exclusively in Canada through CannMart and Namaste sales channels
  • Represents a fundamental step in Namaste’s growth strategy to develop a marketplace

VANCOUVER, British Columbia, Sept. 15, 2017 – Namaste Technologies Inc. (“Namaste” or the “Company”) (CSE:N)(FRANKFURT:M5BQ)(OTCMKTS:NXTTF) is pleased to announce that its wholly owned subsidiary, Cannmart Inc. (“CannMart”), has signed a supply agreement (the “Agreement”) with Israeli-based producer Cannbit Ltd. (“Cannbit”).

The Agreement, subject to approval by Health Canada, will supply medical cannabis products sourced from Cannbit in Israel, to be sold exclusively in Canada through CannMart and Namaste sales channels. This Agreement represents a fundamental step in Namaste’s growth strategy to develop a marketplace for Canadian medical cannabis that will include product sourced both domestically and internationally.

Namaste will further pursue supply agreements with domestic and international producers in developing a unique online platform to provide a larger variety of medical cannabis products to patients sourced from domestic and international producers. Namaste recognizes that Israel is providing the medical cannabis industry with leading research and intends to provide Israeli-grown products to Canadian medical cannabis patients.

Management Commentary

Sean Dollinger, President and CEO of Namaste comments: “We are very pleased to sign this Agreement. We had the opportunity of meeting with the Cannbit management team and feel very strongly that Namaste will bring some of the highest quality medical cannabis available in the world to our Canadian patients. Through our new platform, Namaste MD, we will be offering a full-service platform for users to flow through an initial consultation to issuance of a prescription. They will then be provided with access to our marketplace of medical cannabis products that will be sourced from multiple producers in Canada, as well as countries like Israel, that are innovators in research and development in our industry.”

About Namaste Technologies Inc.

Namaste Technologies Inc. is an emerging leader in vaporizer and accessories space. Namaste has 26 ecommerce retail stores in 20 countries, offers the largest range of brand name vaporizers products on the market and is actively manufacturing and launching multiple unique proprietary products for retail and wholesale distribution. The Company is currently focused on expanding its product offering, acquisitions and strategic partnerships, and entering new markets globally.

On behalf of the Board of Directors

“Sean Dollinger”
Chief Executive Officer
Direct: +1 (786) 389 9771
Email: info@namastevapes.com

Further information on the Company and its products can be accessed through the links below:

www.namastetechnologies.com

www.namastevaporizers.com

www.namastevaporizers.co.uk

www.everyonedoesit.com

www.everyonedoesit.co.uk

FORWARD LOOKING INFORMATION This press release contains forward-looking information based on current expectations. These statements should not be read as guarantees of future performance or results. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements. Although such statements are based on management’s reasonable assumptions, Namaste assumes no responsibility to update or revise forward looking information to reflect new events or circumstances unless required by law. Although the Company believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because the Company can give no assurance that they will prove to be correct. Since forward looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. These statements speak only as of the date of this press release. Actual results could differ materially from those currently anticipated due to a number of factors and risks including various risk factors discussed in the Company’s disclosure documents which can be found under the Company’s profile on www.sedar.com. This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The CSE has neither reviewed nor approved the contents of this press release.

Invested in #MMJ stocks like Cannagrow $CGRW ? Tetra Bio-Pharma $TBP.ca will benefit from IP created at University of New Brunswick

Posted by AGORACOM-JC at 12:36 PM on Thursday, September 14th, 2017

Tbp large new

TBP: TSX-V

WHY TETRA BIO-PHARMA?

  • Only pharmaceutical company to have clinical studies for smoked marijuana;
  • Will benefit from the intellectual property created within the cannabis health research Chair from the University of New Brunswick
  • Company is financially sound, with enough cash to pay for the $1.2 million Phase III clinical trials of PPP001.
  • Preparations for the Phase III trial of PPP001 are to start in Q4 2017 with approximately 600 subjects;
  • Focused on expanding commercialization partnerships internationally for product pipeline – Interest has been shown from the USA, Germany, Ireland, Brazil and Mexico;
  • Initial demand forecasted in New Brunswick for PPP001 using the ACMPR license is more than expected
  • Putting in place the necessary manufacturing capabilities to address this increasing demand and to ensure the highest standards of quality control.

Marijuana Company of America $MCOA Announces the Release of #hempSMART Full Spectrum CBD Drops #MMJ

Posted by AGORACOM-JC at 7:49 AM on Wednesday, September 13th, 2017

15233 mcoa

  • Released its new Full Spectrum Drops, available in 250mg bottles, enriched with non-psychoactive industrial hemp derived CBD
  • Full Spectrum Drops are now available for purchase by Company affiliates and customers at the Company’s newly redesigned website and sales platform for affiliates at www.hempsmart.com.

ESCONDIDO, CA–(Sep 13, 2017) –  MARIJUANA COMPANY OF AMERICA (“MCOA” or the “Company”) (OTC PINK: MCOA), an innovative cannabis research and development and industrial hemp corporation, is pleased to announce that its wholly owned subsidiary, hempSMART™, Inc., today released its new Full Spectrum Drops, available in 250mg bottles, enriched with non-psychoactive industrial hemp derived CBD.

After several months of market research, competitive comparison and product formulation, the proprietary hempSMART™ Full Spectrum Drops are now available for purchase by Company affiliates and customers at the Company’s newly redesigned website and sales platform for affiliates at www.hempsmart.com.

The hempSMART™ Full Spectrum Drops are available in four different flavors: lemon, mint, orange and strawberry, and are formulated with phytocannabinoid rich full spectrum hemp CBD oil that is free of the THC isolate, and provides the desired “Entourage Effect” of naturally occurring CBD, Terpenes, and complimentary Cannabinoids.

Commenting on the product release, Tim Alvater, the Company’s head of marketing, stated, “The opportunity to develop products using the finest ingredients, coupled with quality non-psychoactive CBD and a marketing plan developed by top affiliate marketing people with decades of experience, gives us the green light to aggressively open the channels of distribution in the US as well as on a global scale. We are proud to be at the forefront of the industrial hemp derived CBD revolution.”

Paul Vetter, a member of hempSMART’s Product Development Advisory Board, commented: “hempSMART’s proprietary Full Spectrum industrially derived CBD free of the THC isolate, with its full array of naturally occurring terpenes, takes CBD supplementation to a new level.”

Donald Steinberg, CEO of MCOA, who previously created multiple affiliate based marketing companies, observed: “The public awareness and acceptance of CBD based products is expanding on a global basis, and at hempSMART™ we are prepared to meet this global demand. Along with our team of executives, we have the products in place, the software, the marketing and the affiliate compensation plan to implement our program of market distribution to an affiliate based marketing group promoting our products in the United States.”

About Marijuana Company of America, Inc.
MCOA is a corporation engaged in business including, but not limited to: (1) product research and development of legal hemp-based consumer products containing CBD under the brand name “hempSMART™”, that targets general health and well-being; (2) an affiliate marketing program to promote and sell its legal hemp-based consumer products containing CBD; (3) leasing of real property to separate business entities engaged in the growth and sale of cannabis in those states and jurisdictions where cannabis has been legalized and properly regulated for medicinal and recreations use; and, (4) the expansion of its business into ancillary areas of the legalized cannabis and hemp industry, as the legalized markets and opportunities in this segment mature and develop.

FORWARD LOOKING STATEMENT
This news release contains “forward-looking statements” which are not purely historical and may include any statements regarding beliefs, plans, expectations or intentions regarding the future. Such forward-looking statements include, among other things, the development, costs and results of new business opportunities and words such as “anticipate”, “seek”, intend”, “believe”, “estimate”, “expect”, “project”, “plan”, or similar phrases may be deemed “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with new projects, the future U.S. and global economies, the impact of competition, and the Company’s reliance on existing regulations regarding the use and development of cannabis-based products. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that any beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that any such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in our annual report on Form 10-12G, our quarterly reports on Form 10-Q and other periodic reports filed from time-to-time with the Securities and Exchange Commission. For more information, please visit www.sec.gov.

For more information, please visit the Company’s websites at:
MarijuanaCompanyofAmerica.com
hempSMART.com
agoracom.com/ir/MarijuanaCompanyofAmerica

Marijuana Company of America, Inc.
Investor Relations
1+(888)-777-4362
IR@mcoa.club

Marijuana Company of America $MCOA.us Announces #hempSMART 2.0 With New Website and Affiliate Program

Posted by AGORACOM-JC at 8:54 AM on Thursday, September 7th, 2017

15233 mcoa

  • Announced a major update of hempSMART™, the Company’s wellness focused Cannabidiol (CBD) marketing and distribution division
  • www.hempSmart.com and its network marketing platform have been completely redeveloped
  • Provides a more user friendly experience to its affiliates and customers

ESCONDIDO, CA–(Sep 7, 2017) – MARIJUANA COMPANY OF AMERICA (“MCOA” or the “Company“) (OTC PINK: MCOA), an innovative cannabis and hemp marketing and distribution company, is pleased to announce a major update of hempSMART™, the Company’s wellness focused Cannabidiol (CBD) marketing and distribution division.

The hempSMART website: www.hempSmart.com and its network marketing platform have been completely redeveloped to provide a more user friendly experience to its affiliates and customers, and to also provide users with the comprehensive tools necessary to succeed in the growing $1.9 Trillion Wellness Industry.

The new website and network marketing platform have a significantly improved design, expanded content and a more user friendly e-commerce platform that offers the ability to easily expand due to the flexibility of the business platform it is built on. Affiliate’s will now experience a more effective, reliable and streamlined sales process to rapidly expand the Company’s consumer base and Affiliate success stories.

The new hempSMART Affiliate sales and distribution method is designed to ensure that our Affiliates play a leading role in the rapidly emerging Cannabidiol (CBD) movement within the Wellness Industry. The Company is in ongoing discussions about expanding internationally into multiple countries in 2018.

“The solid foundation that our new system and online platform offers will enable our Affiliates to fully utilize their abilities to grow their organizations in the U.S. and globally. Our team is in place, our products are being well received in the market, and we are in an industry that is experiencing exponential growth. We are building a strong foundation of technology, products and a strategic marketing plan that is designed to offer great benefits to our Affiliates who are the key to our success. We look forward to a robust and exciting time for our company,” said CEO, Donald Steinberg.

About Marijuana Company of America, Inc.

MCOA is a corporation engaged in business including, but not limited to: (1) product research and development of legal hemp-based consumer products containing CBD under the brand name “hempSMART™”, that targets general health and well-being; (2) an affiliate marketing program to promote and sell its legal hemp-based consumer products containing CBD; (3) leasing of real property to separate business entities engaged in the growth and sale of cannabis in those states and jurisdictions where cannabis has been legalized and properly regulated for medicinal and recreations use; and, (4) the expansion of its business into ancillary areas of the legalized cannabis and hemp industry, as the legalized markets and opportunities in this segment mature and develop.

FORWARD LOOKING STATEMENT
This news release contains “forward-looking statements” which are not purely historical and may include any statements regarding beliefs, plans, expectations or intentions regarding the future. Such forward-looking statements include, among other things, the development, costs and results of new business opportunities and words such as “anticipate”, “seek”, intend”, “believe”, “estimate”, “expect”, “project”, “plan”, or similar phrases may be deemed “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with new projects, the future U.S. and global economies, the impact of competition, and the Company’s reliance on existing regulations regarding the use and development of cannabis-based products. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that any beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that any such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in our annual report on Form 10-12G, our quarterly reports on Form 10-Q and other periodic reports filed from time-to-time with the Securities and Exchange Commission. For more information, please visit www.sec.gov.

For more information, please visit the Company’s websites at:
MarijuanaCompanyofAmerica.com
hempSMART.com
agoracom.com/ir/MarijuanaCompanyofAmerica

Marijuana Company of America, Inc.
Investor Relations
1+(888)-777-4362
IR@mcoa.club

Namaste Technologies $N.ca Provides Update on CannMart Inc. – Facility is under review #MMJ #Marijuana #Hemp

Posted by AGORACOM-JC at 10:40 AM on Tuesday, September 5th, 2017

Nlogo

  • Received confirmation from Health Canada that the facility acquired in the acquisition of Cannmart Inc. is under the review stage of its application
  • Under the Access to Cannabis for Medical Purposes Regulations to become a “sales only” licensed producer of medical cannabis

VANCOUVER, British Columbia, Sept. 05, 2017 — Namaste Technologies Inc. (“Namaste” or the “Company”) (CSE:N) (FRANKFURT:M5BQ) (OTCMKTS:NXTTF) is pleased to announce that it has received confirmation from Health Canada that the facility (the “Facility”) acquired in the acquisition of Cannmart Inc. (“CannMart”) is under the review stage of its application (the “Application”) under the Access to Cannabis for Medical Purposes Regulations (the “ACMPR”) to become a “sales only” licensed producer of medical cannabis. Namaste has also engaged David Hyde & Associates to provide security consulting for the Facility and Eurofins Experchem Laboratories Inc. (“Eurofins Experchem”) to consult for CannMart on regulatory compliance.

On August 22, 2017, CannMart received confirmation from Health Canada that it has reached the review stage of the Application, during which Health Canada will be completing a thorough review of the Application. Concurrently, CannMart’s submitted personnel security clearances are being processed. The Security Clearance Application Forms that were submitted as part of the Application will be reviewed for completeness before a request is submitted to the RCMP to conduct a check of the relevant files of law enforcement agencies, including intelligence gathered for law enforcement purposes.

Over the past 4 years, David Hyde & Associates has provided security consulting services to over 165 ACMPR license applicants across Canada, worked with 27 licensed producer sites and attended 22 pre-license inspections with Health Canada. Its 11-member team has extensive experience in security consultation within the regulated medical cannabis sector in Canada and beyond and recently became the first Associate Member of the Cannabis Canada Association.

Eurofins Experchem has been engaged by Namaste to provide regulatory consulting services for CannMart through its final stages of approval from Health Canada. Eurofins Experchem provides a wide range of regulatory and testing services for the Canadian medical cannabis industry, ensuring that facilities comply with the Marihuana for Medical Purposes Regulations.

Management Commentary

Sean Dollinger, President and CEO of Namaste comments: “We are very excited to make this announcement on the progress of activities with our CannMart facility. We are also very much looking forward to working with the teams from both David Hyde & Associates and Eurofins Experchem Laboratories Inc. to consult for CannMart during this stage and once operations at the Facility begin.”

About Namaste Technologies Inc.

Namaste Technologies Inc. is an emerging leader in vaporizer and accessories space. Namaste has 26 ecommerce retail stores in 20 countries, offers the largest range of brand name vaporizers products on the market and is actively manufacturing and launching multiple unique proprietary products for retail and wholesale distribution. The Company is currently focused on expanding its product offering, acquisitions and strategic partnerships, and entering new markets globally.

On behalf of the Board of Directors

“Sean Dollinger”
Chief Executive Officer
Direct: +1 (786) 389 9771
Email: info@namastevapes.com

Further information on the Company and its products can be accessed through the links below:

www.namastetechnologies.com

www.namastevaporizers.com

www.namastevaporizers.co.uk

www.vaporseller.com

www.everyonedoesit.com

www.everyonedoesit.co.uk

FORWARD LOOKING INFORMATION This press release contains forward-looking information based on current expectations. These statements should not be read as guarantees of future performance or results. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements. Although such statements are based on management’s reasonable assumptions, Namaste assumes no responsibility to update or revise forward looking information to reflect new events or circumstances unless required by law. Although the Company believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because the Company can give no assurance that they will prove to be correct. Since forward looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. These statements speak only as of the date of this press release. Actual results could differ materially from those currently anticipated due to a number of factors and risks including various risk factors discussed in the Company’s disclosure documents which can be found under the Company’s profile on www.sedar.com. This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The CSE has neither reviewed nor approved the contents of this press release.

Primary Logo

Marijuana Company of America $MCOA.us Announces Joint Venture in Canada with Global Hemp Group $GHG.ca $GBHPF #MMJ #Hemp

Posted by AGORACOM-JC at 7:54 AM on Tuesday, September 5th, 2017

15233 mcoa

  • Announce a Joint Venture with Global Hemp Group Inc.  on its industrial hemp project on the Acadian peninsula of New Brunswick, Canada
  • MCOA has partnered with GHG to assist in developing commercial hemp production in the region

ESCONDIDO, CA–(Sep 5, 2017) – MARIJUANA COMPANY OF AMERICA INC. (“MCOA” or the “Company“) (OTC: MCOA), an innovative cannabis and hemp corporation, is pleased to announce a Joint Venture (“JV”) with Global Hemp Group Inc. (“GHG”) (CSE: GHG) (OTC: GBHPF) on its industrial hemp project on the Acadian peninsula of New Brunswick, Canada.

MCOA has partnered with GHG to assist in developing commercial hemp production in the region. Currently GHG is conducting its first phase hemp cultivation trials on the peninsula (Please visit the following link for updates — https://globalhempgroup.com/trialupdates). The results of these trials will be used to establish commercial cultivation in 2018. In this first year of the JV, MCOA will share the costs of the ongoing hemp trial; provide its expertise in developing hemp cultivation; and, be granted a Right of First Refusal as GHG’s primary off-taker of any raw materials produced from this project. The project is also receiving research support from Collège Communautaire du Nouveau Brunswick (CCNB) located in Bathurst, New Brunswick.

GHG’s Hemp Argo-Industrial Zones, or HAIZ, concept will help create the infrastructure capable of processing all of the industrial hemp plant into a number of different wholesale products. This concept being developed by GHG, will help create jobs for farmers and provide superior sustainable products to the global market. MCOA and GHG also intend to extract cannabinoids like CBD, CBG, and CBN for the development of MCOA’s proprietary line of hempSMART™ cannabinoid based products.

“Global Hemp Group is providing MCOA an opportunity to expand into the hemp market in Canada. We intend to build upon this relationship between our companies and are excited to take part in this project in New Brunswick,” said MCOA’s CEO Donald Steinberg.

About Global Hemp Group Inc.
Global Hemp Group (“GHG”) is a publicly traded company founded in 2012, headquartered in British Columbia, Canada with base operations in Montreal and Southern California. The Company is focused on the production and processing of hemp and cannabis, and collaboration with companies that will enable GHG to develop and implement the Hemp Agro-Industrial Zone concept. Through partnerships, joint ventures and acquisitions, the Company will capture cash flow, revenues and value, and establish a greater collective valuation.

About Marijuana Company of America, Inc.
MCOA is a corporation engaged in business including, but not limited to: (1) product research and development of legal hemp-based consumer products containing CBD under the brand name “hempSMART™”, that targets general health and well-being; (2) an affiliate marketing program to promote and sell its legal hemp-based consumer products containing CBD; (3) leasing of real property to separate business entities engaged in the growth and sale of cannabis in those states and jurisdictions where cannabis has been legalized and properly regulated for medicinal and recreations use; and, (4) the expansion of its business into ancillary areas of the legalized cannabis and hemp industry, as the legalized markets and opportunities in this segment mature and develop.

Forward Looking Statements
This news release contains “forward-looking statements” which are not purely historical and may include any statements regarding beliefs, plans, expectations or intentions regarding the future. Such forward-looking statements include, among other things, the development, costs and results of new business opportunities and words such as “anticipate”, “seek”, intend”, “believe”, “estimate”, “expect”, “project”, “plan”, or similar phrases may be deemed “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with new projects, the future U.S. and global economies, the impact of competition, and the Company’s reliance on existing regulations regarding the use and development of cannabis-based products. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that any beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that any such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in our annual report on Form 10-12G, our quarterly reports on Form 10-Q and other periodic reports filed from time-to-time with the Securities and Exchange Commission. For more information, please visit www.sec.gov.

For more information, please visit the Company’s websites at:
MarijuanaCompanyofAmerica.com
hempSMART.com
agoracom.com/ir/MarijuanaCompanyofAmerica

MARIJUANA COMPANY OF AMERICA INC.
Investor Relations
1+(888)-777-4362
IR@mcoa.club

Invested in #MMJ stocks such as #Cannabis Sativa $CBDS? Check out the world’s largest B2C #Vaporizer company Namaste $N.ca

Posted by AGORACOM-JC at 2:43 PM on Friday, September 1st, 2017

Nlogo

  • World’s Largest E-Commerce B2C Vaporizer Company
  • Record Monthly Sales of CAD$1.349M For June 2017
  • Revenue for AUG 31 2018 expected $24.9 million
  • Owns 26 e-commerce stores in 20 countries
  • Distribution centers in North America, South America, Europe and Asia Pacific
  • Aggressively expanding into manufacturing and wholesaling

Interested AeroGrow $AERO ? Check out Tetra Bio-Pharma $TBP.ca $TBPMF

Posted by AGORACOM-JC at 11:47 AM on Tuesday, August 29th, 2017

Tbp large new

WHY TETRA BIO-PHARMA?

  • Only pharmaceutical company to have clinical studies for smoked marijuana;
  • Company is financially sound, with enough cash to pay for the $1.2 million Phase III clinical trials of PPP001.
  • Preparations for the Phase III trial of PPP001 are to start in Q4 2017 with approximately 600 subjects;
  • Focused on expanding commercialization partnerships internationally for product pipeline – Interest has been shown from the USA, Germany, Ireland, Brazil and Mexico;
  • Initial demand forecasted in New Brunswick for PPP001 using the ACMPR license is more than expected
  • Putting in place the necessary manufacturing capabilities to address this increasing demand and to ensure the highest standards of quality control.